|
1
|
Tsai RY and McKay RD: A nucleolar
mechanism controlling cell proliferation in stem cells and cancer
cells. Genes Dev. 16:2991–3003. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu SJ, Cai ZW, Liu YJ, Dong MY, Sun LQ,
Hu GF, Wei YY and Lao WD: Role of nucleostemin in growth regulation
of gastric cancer, liver cancer and other malignancies. World J
Gastroenterol. 10:1246–1249. 2004.PubMed/NCBI
|
|
3
|
Uema N, Ooshio T, Harada K, Naito M, Naka
K, Hoshii T, Tadokoro Y, Ohta K, Ali MA, Katano M, et al: Abundant
nucleostemin expression supports the undifferentiated properties of
germ cell tumors. Am J Pathol. 183:592–603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu RL, Xu Y, Zhang ZH, Wang M, Sun JT, Qi
SY, Zhang Y and Li SZ: Expression of nucleostemin in prostate
cancer tissues and its clinical significance. Natl J Androl.
14:418–422. 2008.In Chinese.
|
|
5
|
Zhang GY, Yin L, Li SL, Xing WY, Zhao QM,
Le XP, Gao DL, Chen KS, Zhang YH and Zhang QX: Expression of
nucleostemin mRNA and protein in the esophageal squamous cell
carcinoma. Chin J Oncol. 30:125–128. 2008.In Chinese.
|
|
6
|
Guo Y, Liao YP, Zhang D, Xu LS, Li N, Guan
WJ and Liu CQ: In vitro study of nucleostemin as a potential
therapeutic target in human breast carcinoma SKBR-3 cells. Asian
Pac J Cancer Prev. 15:2291–2295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Asadi MH, Derakhshani A and Mowla SJ:
Concomitant upregulation of nucleostemin and downregulation of Sox2
and Klf4 in gastric adenocarcinoma. Tumour Biol. 35:7177–7185.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi T, Masutomi K, Tamura K, Moriya
T, Yamasaki T, Fujiwara Y, Takahashi S, Yamamoto J and Tsuda H:
Nucleostemin expression in invasive breast cancer. BMC Cancer.
14:2152014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
You Y, Li X, Zheng J, Wu Y, He Y, Du W,
Zou P and Zhang M: Transcript level of nucleostemin in newly
diagnosed acute myeloid leukemia patients. Leuk Res. 37:1636–1641.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sijin L, Ziwei C, Yajun L, Meiyu D,
Hongwei Z, Guofa H, Siguo L, Hong G, Zhihong Z, Xiaolei L, et al:
The effect of knocking-down nucleostemin gene expression on the in
vitro proliferation and in vivo tumorigenesis of HeLa cells. J Exp
Clin Cancer Res. 23:529–538. 2004.PubMed/NCBI
|
|
11
|
Ma H and Pederson T: Depletion of the
nucleolar protein nucleostemin causes G1 cell cycle arrest via the
p53 pathway. Mol Biol Cell. 18:2630–2635. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu RL, Zhang ZH, Zhao WM, Wang M, Qi SY,
Li J, Zhang Y, Li SZ and Xu Y: Expression of nucleostemin in
prostate cancer and its effect on the proliferation of PC-3 cells.
Chin Med J (Engl). 121:299–304. 2008.
|
|
13
|
Seyed-Gogani N, Rahmati M, Zarghami N,
Asvadi-Kermani I, Hoseinpour-Feyzi MA and Moosavi MA: Nucleostemin
depletion induces post-g1 arrest apoptosis in chronic myelogenous
leukemia k562 cells. Adv Pharm Bull. 4:55–60. 2014.PubMed/NCBI
|
|
14
|
Amini S, Fathi F, Mobalegi J,
Sofimajidpour H and Ghadimi T: The expressions of stem cell
markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3,
Dppa4 and Esrrb in bladder, colon and prostate cancer and certain
cancer cell lines. Anat Cell Biol. 47:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beekman C, Nichane M, De Clercq S, Maetens
M, Floss T, Wurst W, Bellefroid E and Marine JC: Evolutionarily
conserved role of nucleostemin: Controlling proliferation of
stem/progenitor cells during early vertebrate development. Mol Cell
Biol. 26:9291–9301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jafarnejad SM, Mowla SJ and Matin MM:
Knocking-down the expression of nucleostemin significantly
decreases rate of proliferation of rat bone marrow stromal stem
cells in an apparently p53-independent manner. Cell Prolif.
41:28–35. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nikpour P, Mowla SJ, Jafarnejad SM,
Fischer U and Schulz WA: Differential effects of Nucleostemin
suppression on cell cycle arrest and apoptosis in the bladder
cancer cell lines 5637 and SW1710. Cell Prolif. 42:762–769. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lo D, Zhang Y, Dai MS, Sun XX, Zeng SX and
Lu H: Nucleostemin stabilizes ARF by inhibiting the ubiquitin
ligase ULF. Oncogene. 34:1688–1697. 2015. View Article : Google Scholar
|
|
19
|
Li X, Zhou J, Chen ZR and Chng WJ: P53
mutations in colorectal cancer-molecular pathogenesis and
pharmacological reactivation. World J Gastroenterol. 21:84–93.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun X, Jia Y, Wei Y, Liu S and Yue B: Gene
expression profiling of HL-60 cells following knockdown of
nucleostemin using DNA microarrays. Oncol Rep. 32:739–747.
2014.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Liu R, Zhang Z and Xu Y: Downregulation of
nucleostemin causes G1 cell cycle arrest via a p53-independent
pathway in prostate cancer PC-3 cells. Urol Int. 85:221–227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zwolinska AK, Heagle Whiting A, Beekman C,
Sedivy JM and Marine JC: Suppression of Myc oncogenic activity by
nucleostemin haploinsufficiency. Oncogene. 31:3311–3321. 2012.
View Article : Google Scholar :
|
|
24
|
Paridaen JT, Janson E, Utami KH, Pereboom
TC, Essers PB, Rooijen C, Zivkovic D and MacInnes AW: The nucleolar
GTP-binding proteins Gnl2 and nucleostemin are required for retinal
neurogenesis in developing zebrafish. Dev Biol. 355:286–301. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stolz A and Wolf DH: Endoplasmic reticulum
associated protein degradation: A chaperone assisted journey to
hell. Biochim Biophys Acta. 1803:694–705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Määttänen P, Gehring K, Bergeron JJ and
Thomas DY: Protein quality control in the ER: The recognition of
misfolded proteins. Semin Cell Dev Biol. 21:500–411. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu XL: The regulative mechanism of
organisms against stress injuries. Biofactors. 40:569–585. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu W, Hagiwara D, Morishita Y, Tochiya M,
Azuma Y, Suga H, Goto M, Banno R, Sugimura Y, Oyadomari S, et al:
Unfolded protein response in hupothalamic cultures of wild-type and
ATF6α-knockout mice. Neurosci Lett. 612:199–203. 2015. View Article : Google Scholar
|
|
29
|
Rao RV, Castro-Obregon S, Frankowski H,
Schuler M, Stoka V, Del RG, Bredesen DE and Ellerby HM: Coupling
endoplasmic reticulum stress to the cell death program. An
Apaf-1-independent intrinsic pathway. J Biol Chem. 277:21836–21842.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szegezdi E, Logue SE, Gorman AM and Samali
A: Mediators of endoplasmic reticulum stress-induced apoptosis.
EMBO Rep. 7:880–885. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang ZX: Neuronal growth-inhibitory
factor (metallo-thionein-3): A unique metalloprotein. FEBS J.
277:29112010. View Article : Google Scholar
|
|
33
|
Vašák M and Meloni G: Chemistry and
biology of mammalian metallothioneins. J Biol Inorg Chem.
16:1067–1078. 2011. View Article : Google Scholar
|
|
34
|
Eide DJ: The oxidative stress of zinc
deficiency. Metallomics. 3:1124–1129. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miura T, Muraoka S and Ogiso T:
Antioxidant activity of metallothionein compared with reduced
glutathione. Life Sci. 60:301–309. 1997. View Article : Google Scholar
|
|
36
|
Ghoshal K and Jacob ST: Regulation of
metallothionein gene expression. Prog Nucleic Acid Res Mol Biol.
66:357–384. 2001. View Article : Google Scholar
|
|
37
|
Günes C, Heuchel R, Georgiev O, Müller KH,
Lichtlen P, Bluthmann H, Marino S, Aguzzi A and Schaffner W:
Embryonic lethality and liver degeneration in mice lacking the
metal-responsive transcriptional activator MTF-1. EMBO J.
17:2846–2854. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Klassen RB, Crenshaw K, Kozyraki R,
Verroust PJ, Tio L, Atrian S, Allen PL and Hammond TG: Megalin
mediates renal uptake of heavy metal metallothionein complexes. Am
J Physiol Renal Physiol. 287:F393–F403. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi Y, Amin K, Sato BG, Samuelsson SJ,
Sambucetti L, Haroon ZA, Laderoute K and Murphy BJ: The
metal-responsive transcription factor-1 protein is elevated in
human tumors. Cancer Biol Ther. 9:469–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cherian MG and Apostolova MD: Nuclear
localization of metallothionein during cell proliferation and
differentiation. Cell Mol Biol (Noisy-le-grand). 46:347–356.
2000.
|
|
41
|
Ogra Y and Suzuki KT: Nuclear trafficking
of metallothionein: Possible mechanisms and current knowledge. Cell
Mol Biol (Noisy-le-grand). 46:357–365. 2000.
|
|
42
|
Knipp M: Metallothioneins and platinum
(II) anti-tumor compounds. Curr Med Chem. 16:522–537. 2009.
View Article : Google Scholar
|
|
43
|
Boulikas T and Vougiouka M: Cisplatin and
platinum drugs at the molecular level (Review). Oncol Rep.
10:1663–1682. 2003.PubMed/NCBI
|
|
44
|
McGee HM, Woods GM, Bennett B and Chung
RS: The two faces of metallothionein in carcinogenesis:
Photoprotection against UVR-induced cancer and promotion of tumour
survival. Photochem Photobiol Sci. 9:586–596. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dutsch-Wicherek M, Sikora J and
Tomaszewska R: The possible biological role of metallothionein in
apoptosis. Front Biosci. 13:4029–4038. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gomulkiewicz A, Podhorska-Okolow M, Szulc
R, Smorag Z, Wojnar A, Zabel M and Dziegiel P: Correlation between
metallothionein (MT) expression and selected prognostic factors in
ductal breast cancers. Folia Histochem Cytobiol. 48:242–248. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Królicka A, Kobierzycki C, Puła B,
Podhorska-Okołów M, Piotrowska A, Rzeszutko M, Rzeszutko W,
Rabczyński J, Domosławski P, Wojtczak B, et al: Comparison of
metallo-thionein (MT) and Ki-67 antigen expression in benign and
malignant thyroid tumours. Anticancer Res. 30:4945–4949. 2010.
|
|
48
|
Kishton RJ and Rathmell JC: Novel
therapeutic targets of tumor metabolism. Cancer J. 21:62–69. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gottfried E, Kreutz M and Mackensen A:
Tumor metabolism as modulator of immune response and tumor
progression. Semin Cancer Biol. 22:335–341. 2012. View Article : Google Scholar : PubMed/NCBI
|
